| DNA sensing in mismatch repair-deficient tumor cells is essential for anti-tumor immunity C Lu, J Guan, S Lu, Q Jin, B Rousseau, T Lu, D Stephens, H Zhang, J Zhu, ... Cancer cell 39 (1), 96-108. e6, 2021 | 177 | 2021 |
| A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control Z Sun, Z Ren, K Yang, Z Liu, S Cao, S Deng, L Xu, Y Liang, J Guo, Y Bian, ... Nature communications 10 (1), 3874, 2019 | 161 | 2019 |
| Targeting tumors with IL-10 prevents dendritic cell-mediated CD8+ T cell apoptosis J Qiao, Z Liu, C Dong, Y Luan, A Zhang, C Moore, K Fu, J Peng, Y Wang, ... Cancer cell 35 (6), 901-915. e4, 2019 | 120 | 2019 |
| Dual targeting of innate and adaptive checkpoints on tumor cells limits immune evasion X Liu, L Liu, Z Ren, K Yang, H Xu, Y Luan, K Fu, J Guo, H Peng, M Zhu, ... Cell reports 24 (8), 2101-2111, 2018 | 101 | 2018 |
| Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling C Han, Z Liu, Y Zhang, A Shen, C Dong, A Zhang, C Moore, Z Ren, C Lu, ... Nature immunology 21 (5), 546-554, 2020 | 92 | 2020 |
| Telomere stress potentiates STING-dependent anti-tumor immunity I Mender, A Zhang, Z Ren, C Han, Y Deng, S Siteni, H Li, J Zhu, A Vemula, ... Cancer cell 38 (3), 400-411. e6, 2020 | 81 | 2020 |
| Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance Y Liang, H Tang, J Guo, X Qiu, Z Yang, Z Ren, Z Sun, Y Bian, L Xu, H Xu, ... Nature communications 9 (1), 4586, 2018 | 78 | 2018 |
| Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity Z Ren, A Zhang, Z Sun, Y Liang, J Ye, J Qiao, B Li, YX Fu The Journal of clinical investigation 132 (3), 2022 | 48 | 2022 |
| CTLA-4 limits anti-CD20–mediated tumor regression Z Ren, J Guo, J Liao, Y Luan, Z Liu, Z Sun, X Liu, Y Liang, H Peng, YX Fu Clinical Cancer Research 23 (1), 193-203, 2017 | 48 | 2017 |
| Dual targeting of CTLA-4 and CD47 on Treg cells promotes immunity against solid tumors A Zhang, Z Ren, KF Tseng, X Liu, H Li, C Lu, Y Cai, JD Minna, YX Fu Science translational medicine 13 (605), eabg8693, 2021 | 47 | 2021 |
| PD-1 shapes B cells as evildoers in the tumor microenvironment Z Ren, H Peng, YX Fu Cancer discovery 6 (5), 477-478, 2016 | 36 | 2016 |
| Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity Z Liu, C Han, C Dong, A Shen, E Hsu, Z Ren, C Lu, L Liu, A Zhang, ... Science immunology 4 (38), eaav6473, 2019 | 35 | 2019 |
| IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8+ T cells to overcome immunotherapy resistance in cancer J Bae, L Liu, C Moore, E Hsu, A Zhang, Z Ren, Z Sun, X Wang, J Zhu, ... Nature cell biology 24 (12), 1754-1765, 2022 | 24 | 2022 |
| Converting lymphoma cells into potent antigen-presenting cells for interferon-induced tumor regression J Liao, Y Luan, Z Ren, X Liu, D Xue, H Xu, Z Sun, K Yang, H Peng, YX Fu Cancer immunology research 5 (7), 560-570, 2017 | 12 | 2017 |
| ZMYND8 expression in breast cancer cells blocks T-lymphocyte surveillance to promote tumor growth Y Wang, M Luo, Y Chen, Y Wang, B Zhang, Z Ren, L Bao, Y Wang, ... Cancer research 81 (1), 174-186, 2021 | 11 | 2021 |
| Bacteria-derived nanovesicles enhance tumour vaccination by trained immunity G Liu, N Ma, K Cheng, Q Feng, X Ma, Y Yue, Y Li, T Zhang, X Gao, ... Nature Nanotechnology, 1-12, 2023 | 4 | 2023 |
| Author Correction: A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control Z Sun, Z Ren, K Yang, Z Liu, S Cao, S Deng, L Xu, Y Liang, J Guo, Y Bian, ... Nature communications 11 (1), 1716, 2020 | 3 | 2020 |
| Degradation of CTLA-4 balances toxicity and efficacy Z Ren, YX Fu Science Bulletin 64 (19), 1388-1389, 2019 | 2 | 2019 |
| Facts and hopes on chimeric cytokine agents for cancer immunotherapy Z Ren, X Zhang, YX Fu Clinical Cancer Research, OF1-OF14, 2024 | 1 | 2024 |
| 1236 Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity Z Ren, A Zhang, YX Fu Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
Yang-Xin FuTsinghua UniversityΗ διεύθυνση ηλεκτρονικού ταχυδρομείου έχει επαληθευτεί στον τομέα tsinghua.edu.cn
